Open AccessLetermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients
Author(s) -
Cameron M. Douglas,
R. Barnard,
Daniel Holder,
Randi Y. Leavitt,
Diane Levitan,
Maureen G. Maguire,
David C. Nickle,
Valerie Teal,
Hong Wan,
Dirk C.J.G. van Alewijk,
Leen Jan Van Doorn,
Sunwen Chou,
Julie Strizki
Publication year - 2019
Publication title -
the journal of infectious diseases (online. university of chicago press)/the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jiz577
Subject(s) - cytomegalovirus , medicine , hematopoietic stem cell , hematopoietic stem cell transplantation , clinical trial , stem cell , hematopoietic cell , virology , immunology , haematopoiesis , intensive care medicine , transplantation , biology , human immunodeficiency virus (hiv) , herpesviridae , viral disease , genetics
Letermovir (LET), a cytomegalovirus (CMV) deoxyribonucleic acid (DNA) terminase inhibitor, was recently approved for prophylaxis of CMV infection in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation. Cytomegalovirus genotyping was performed to identify LET-resistance-associated variants (RAVs) among subjects in a Phase 3 trial.